Response of factor V inhibitor to rituximab in a patient who received liver transplantation for primary biliary cirrhosis
- 18 November 2004
- journal article
- case report
- Published by Wiley in American Journal of Hematology
- Vol. 77 (4) , 363-365
- https://doi.org/10.1002/ajh.20181
Abstract
A 43‐year‐old patient developed factor V inhibitor 6 months after liver transplantation for primary biliary cirrhosis in association with Sjögren's syndrome/systemic lupus erythematosus. She suffered from ecchymoses in the lower extremities. The factor V inhibitor was eradicated after 10 weekly doses of 375–500 mg/m2 rituximab. Am. J. Hematol. 77:363–365, 2004.Keywords
This publication has 13 references indexed in Scilit:
- Massive Blutungsneigung bei zwei Patienten mit Faktor-V-Hemmkörper und Anti-Phospholipid-Antikörpern nach Ciprofloxacin-EinnahmeMedizinische Klinik, 2003
- Rituximab in the treatment of acquired factor VIII inhibitorsBlood, 2002
- High‐titer acquired factor V inhibitor responsive to corticosteroids and cyclophosphamide in a patient with two malignant tumorsAmerican Journal of Hematology, 2002
- Treatment of relapsed idiopathic thrombocytopenic purpura with the anti‐CD20 monoclonal antibody rituximab: a pilot studyEuropean Journal of Haematology, 2002
- Isolation and characterization of an antifactor V antibody causing activated protein C resistance from a patient with severe thrombotic manifestationsBlood, 2002
- Rituximab Therapy for Refractory Thrombotic Thrombocytopenic PurpuraBlood Cells, Molecules, and Diseases, 2002
- INHIBITOR AGAINST COAGULATION FACTOR V AFTER LIVER TRANSPLANTATIONTransplantation, 1999
- Factor V inhibitor associated with Sjögren's syndromeBritish Journal of Haematology, 1995
- Fibrin glue in surgery: frequent development of inhibitors of bovine thrombin and human factor VBritish Journal of Haematology, 1993
- A Circulating Factor V Inhibitor: Possible Side Effect of Treatment with StreptomycinScandinavian Journal of Haematology, 1975